Bristol-Myers Squibb: Can This Pharma Giant Rebound?

Is Bristol-Myers Squibb a buy despite recent struggles? The pharmaceutical giant is down 25% from its high, underperforming the market despite a revenue beat. We dissect the factors impacting the stock's slump, from generic competition affecting legacy drugs to lowered earnings guidance. Discover why analysts are cautiously optimistic, with a potential 10% upside, and whether this pharma heavyweight can regain its footing. Hosted on Acast. See acast.com/privacy for more information.